Table 2 Dose modification

From: Phase II study of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with stage IIIb and IV non-small-cell lung cancer

  

Reasons for cessation of irinotecan treatment

 

Course

No. of patients

On Day 8

 

On Day 15

 

Dose intensity

First

50

Total

4

Total

12

90.0

  

Brain infarction

1

Brain infarction

1

 
  

Infection

1

Pneumonitis

1

 
  

Thrombocytopenia

1

Diarrhoea

1

 
  

Diarrhoea

1

Leucopenia

6

 
    

Thrombocytopenia

2

 
    

Leucopenia and Thrombocytopenia

1

 

Second

49

Total

0

Total

12

89.5

   

1

Infection

1

 
    

Leucopenia

6

 
    

Thrombocytopenia

3

 
    

Leucopenia and Thrombocytopenia

1

 

Third

39

Total

1

Total

19

78.5

  

Leucopenia

 

Leucopenia

5

 
    

Thrombocytopenia

7

 
    

Leucopenia and Thrombocytopenia

7